Liquid Biopsy as Surrogate to Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis towards Precision Medicine
journal contributionposted on 2023-08-30, 16:28 authored by Claudio Luchini, Nicola Veronese, Alessia Nottegar, Vera Cappelletti, Maria Daidone, Lee Smith, Christopher N. Parris, Lodewijk Brosens, Maria G. Caruso, Liang Cheng, Christopher Wolfgang, Laura Wood, Michele Milella, Roberto Salvia, Aldo Scarpa
Liquid biopsy (LB) is a non-invasive approach representing a promising tool for new precision medicine strategies for cancer treatment. However, a comprehensive analysis of its reliability for pancreatic cancer (PC) is lacking. To this aim, we performed the first meta-analysis on this topic. We calculated the pooled sensitivity, specificity, positive (LR+) and negative (LR−) likelihood ratio, and diagnostic odds ratio (DOR). A summary receiver operating characteristic curve (SROC) and area under curve (AUC) were used to evaluate the overall accuracy. We finally assessed the concordance rate of all mutations detected by multi-genes panels. Fourteen eligible studies involving 369 patients were included. The overall pooled sensitivity and specificity were 0.70 and 0.86, respectively. The LR+ was 3.85, the LR- was 0.34 and DOR was 15.84. The SROC curve with AUC of 0.88 indicated a relatively high accuracy of LB for molecular characterization of PC. The concordance rate of all mutations detected by multi-genes panels was 31.9%. LB can serve as surrogate to tissue in molecular profiling of PC, because of its relatively high sensitivity, specificity and accuracy. It represents a unique opportunity to be further explored towards its introduction in clinical practice and for developing new precision medicine approaches against PC.
- Accepted version